Cytotoxic T-cell immunity against telomerase reverse transcriptase in colorectal cancer patients

Oncology Reports

Volumn 12, Issue 4, 2004, Pages 871-876

  Titu, Liviu V ^a   Loveday, Ruth L ^a   Madden, Leigh A ^a   Cawkwell, Lynn ^a   Monson, John R ^a   Greenman, John ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Colorectal cancer; Immunity; Telomerase

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; DNA BINDING PROTEIN; EPITOPE; GAMMA INTERFERON; HLA A2 ANTIGEN; M1 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; PEPTIDE FRAGMENT; TELOMERASE;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CELLULAR IMMUNITY; CHEMISTRY; COLORECTAL TUMOR; COMPARATIVE STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; HUMAN; IMMUNOLOGY; INFLUENZA VIRUS A; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; DNA-BINDING PROTEINS; EPITOPES; FEMALE; HLA-A2 ANTIGEN; HUMANS; IMMUNITY, CELLULAR; INFLUENZA A VIRUS; INTERFERON TYPE II; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; TELOMERASE; VIRAL MATRIX PROTEINS;

EID: 16644376274     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.12.4.871     Document Type: Article

References (36)

1. Mocellin S, Rossi CR, Lise M and Marincola FM: Adjuvant immunotherapy for solid tumors: from promise to clinical application. Cancer Immunol Immunother 51: 583-595, 2002. (Pubitemid 35440511)
2. Gordan JD and Vonderheide RH. Universal tumor antigens as targets for immunotherapy. Cytotherapy 4: 317-327, 2002.
3. Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM and Anichini A: Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 94: 805-818, 2002. (Pubitemid 34705052)
4. Rosenberg S A: A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10: 281-287, 1999.
5. Kim NW, Piatyszek MA, Prowse KR, et al: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994.
6. Shay JW and Wright WE: Telomerase: a target for cancer therapeutics. Cancer Cell 2: 257-265, 2002. (Pubitemid 41043959)
7. Nakamura TM and Cecil TR: Reversing time: origin of telomerase. Cell 92: 587-590, 1998. (Pubitemid 28141505)
8. Avilion AA, Piatyszek MA, Gupta J, Shay JW, Bacchetti S and Greider CW: Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res 56: 645-650, 1996. (Pubitemid 26043667)
9. Bodnar AG, Ouellette M, Frolkis M, et al: Extension of life-span by introduction of telomerase into normal human cells. Science 279: 349-352, 1998. (Pubitemid 28063364)
10. Nakayama J, Tahara H, Tahara E, et al: Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 18: 65-68, 1998. (Pubitemid 28027882)
11. Vonderheide RH: Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 21: 674-679, 2002.
12. Scheibenbogen C, Lee KH, Mayer S, Stevanovic S, Moebius U, Herr W, Rammensee HG and Keilholz U: A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin Cancer Res 3: 221-226, 1997. (Pubitemid 27107298)
13. Scheibenbogen C, Lee KH, Stevanovic S, et al: Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. Int J Cancer 71: 932-936, 1997. (Pubitemid 27252870)
14. Vonderheide RH, Hahn WC, Schultze JL and Nadler LM: The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10: 673-679, 1999. (Pubitemid 29302920)
15. Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P and Zanetti M: Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA 97: 4796-4801, 2000. (Pubitemid 30238637)
16. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM and Schlom J: Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 87: 982-990, 1995.
17. Lehner PJ, Wang EC, Moss PA, et al: Human HLA-A0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T cells bearing the V beta 17 gene segment. J Exp Med 181: 79-91, 1995.
18. Pittet MJ, Valmori D, Dunbar PR, et al: High frequencies of naive Melan-A/MART-1- specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 190: 705-715, 1999. (Pubitemid 29428652)
19. Tahara H, Yasui W, Tahara E, et al: Immunohistochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene 18: 1561-1567, 1999. (Pubitemid 29108056)
20. Hayne D, Brown RS, McCormack M, Quinn MJ, Payne HA and Babb P: Current trends in colorectal cancer: site, incidence, mortality and survival in England and Wales. Clin Oncol 13: 448-452, 2001. (Pubitemid 34071945)
21. Kaklamanis L, Gatter KC, Hill AB, et al: Loss of HLA class-I alleles, heavy chains and beta 2-microglobulin in colorectal cancer. Int J Cancer 51: 379-385, 1992.
22. Browning MJ, Krausa P, Rowan A, Hill AB, Bicknell DC, Bodmer JG and Bodmer WF: Loss of human leukocyte antigen expression on colorectal tumor cell lines: implications for antitumor immunity and immunotherapy. J Immunother 14: 163-168, 1993. (Pubitemid 23319203)
23. Gilboa E: How tumors escape immune destruction and what we can do about it. Cancer Immunol Immunother 48: 382-385, 1999.
24. Engelhardt M, Drullinsky P, Guillem J and Moore MA: Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. Clin Cancer Res 3: 1931-1941, 1997. (Pubitemid 27505118)
25. Shay JW and Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 33: 787-791, 1997.
26. Rosenberg SA, Young JC, Schwartzentruber DJ, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4: 321-327, 2000.
27. Zeh HJ, Stanley-O'Carroll K and Chati MA: Vaccines for colorectal cancer. Trends Mol Med 7: 307-313, 2002.
28. Dudley ME, Wunderlich JR, Robbins PF, et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumour lymphocytes. Science 298: 850-854, 2002. (Pubitemid 35231542)
29. Wong LX, Chen BG and Plautz GE: Adoptive immunotherapy of advanced tumors with CD62 L-selective (low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion. J Immunol 169: 3314-3320, 2002.
30. Nagorsen D, Keilholz U, Rivoltini L, et al: Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. Cancer Res 60: 4850-4854, 2000.
31. Lev A, Denkberg G, Cohen CJ, et al: Isolation and characterisation of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Cancer Res 62: 3184-3194, 2002. (Pubitemid 34602412)
32. Vonderheide RH, Schultze JL, Anderson KS, et al: Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res 61: 8366-8370, 2001. (Pubitemid 33131106)
33. Ayyoub M, Migliaccio M, Guillaume P, et al: Lack of tumor recognition by hTert peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. Eur J Immunol 31: 2642-2651, 2001. (Pubitemid 32898731)
34. Shaif-Muthana M, Mclntyre C, Sisley K, Rennie I and Murray A: Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells. Cancer Res 60: 6441-6447, 2000.
35. Greenfield EA, Naguyen KA and Kuchroo VK: CD28/B7 costimulation: a review. Crit Rev Immunol 18: 389-418, 1998. (Pubitemid 28447017)
36. Hermans IF, Daish A, Yang G, Ritchie DS and Ronchese F. Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors. Cancer Res 58: 3909-3917, 1998. (Pubitemid 28405648)